Liquid Biosciences

Liquid Biosciences is a company specializing in bio-analytics with a focus on advancing the understanding of patient outcomes. Their flagship product, Emerge, is a technology platform designed to accurately identify the biological and behavioral factors influencing patient health. This innovative approach has positioned Liquid Biosciences as a valuable partner to major biotech, pharma, and diagnostic companies, offering the potential to reduce development costs, risk, and time by 50%. With a track record of 200 projects across 45 diseases in 10 years, their platform boasts a 100% reproducibility rate, underscoring the reliability and effectiveness of their solutions. Founded in 2011, Liquid Biosciences operates in the space of Analytics, Biotechnology, Health Care, Life Sciences, and Pharmaceuticals, showcasing a diversified portfolio that aligns with key industry trends. The company's most recent investment, a Seed Round secured on 30th October 2018, was supported by Tech Coast Angels, a well-known investment firm. This funding round serves as a testament to the confidence investors have in Liquid Biosciences and its potential to drive innovation within the biotech and healthcare sectors.